<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280538</url>
  </required_header>
  <id_info>
    <org_study_id>NOVA-FCM-Rheuma-2</org_study_id>
    <nct_id>NCT02280538</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of Hyaluronic Acid in Primary Knee OA</brief_title>
  <acronym>ViscOA</acronym>
  <official_title>A Randomized Placebo Controlled Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Repeated Intra-articular Injections of Hyaluronic Acid in Primary Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Nova de Lisboa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Medical School (FCM-UNL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Estudos de Doenças Crónicas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Santa Maria, Portugal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Egas Moniz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Medicina Molecular João Lobo Antunes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Nova de Lisboa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to test the hypothesis that Intra-Articular Hyaluronic Acid
      (IAHA) is superior to placebo in slowing structural progression and on long term symptomatic
      effect in primary knee Osteoarthritis (OA) patients.

      The investigators will perform a multicenter double-blind, randomized, placebo-controlled,
      parallel group trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population will be patients with the diagnosis of knee osteoarthritis who are
      followed at two Portuguese hospitals (Centro Hospitalar de Lisboa Norte - Hospital Santa
      Maria, Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz).

      All patients selected will be included in the intention-to-treat group. Then, using blocked
      randomization method they will be assigned to receive either IAHA, or placebo (saline
      solution). At both hospitals the study will consist of four injections of IAHA, 6 months
      apart, plus a 6 month period after the injection, resulting in a total follow-up period of 24
      months. Before each new cycle a follow-up consultation will be performed in order to assess
      pain and function (KOOS), quality of life (SF-36), adverse events and consumption of
      acetaminophen and NSAIDS regarding the week before evaluation. X-rays will be performed in
      the beginning of follow-up, one year after that and 6 months after the last cycle of IAHA or
      placebo injections (24 months).

      Ultrasound evaluation will be performed at the target knee in same time points as X-rays by
      two rheumatologists trained in musculoskeletal ultrasound examination. Additionally, the
      investigators will assess potential biochemical biomarkers of knee OA structural progression
      and response to treatment. Measurements will be performed in both serum and urine and, If
      possible, synovial fluid aspiration will be performed and together with blood and urine
      samples stored at the Biobanco-IMM Instituto de Medicina Molecular for analysis. Biologic
      samples collection will be performed at baseline and repeated at the 4th, 12th, 24th, 36th
      weeks, and then every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint Space Width</measure>
    <time_frame>2 years</time_frame>
    <description>Mean change of minimal JSW of the most affected compartment of the tibiofemural joint in both placebo and IAHA groups at the end of follow-up (2 years).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT/OARSI 2004 response</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients achieving symptomatic relief according to OMERACT/OARSI 2004 response criteria at 6 months of follow-up in both placebo and IAHA groups. OMERACT/OARSI 2004 will be determined using KOOS questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT/OARSI 2004 response</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients achieving symptomatic relief according to OMERACT/OARSI 2004 criteria at each follow-up visit. OMERACT/OARSI 2004 will be determined using KOOS questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocurrence of Knee replacement surgery</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients submitted to knee replacement surgery at the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen Consumption</measure>
    <time_frame>2 years</time_frame>
    <description>Mean consumption of acetaminophen (mg/day) at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NSAIDs</measure>
    <time_frame>2 years</time_frame>
    <description>Mean consumption of NSAIDs (mg/day) at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire - Physical Score</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of SF-36 questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 questionnaire - Mental Score</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of SF-36 questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro QoL 5D</measure>
    <time_frame>2 years</time_frame>
    <description>Mean score of Euro QoL 5D questionnaire at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of adverse events occurring on both placebo and IAHA groups at each follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Mean VAS score at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>2 years</time_frame>
    <description>Mean VAS score at each follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteoarthritis Of Knee</condition>
  <arm_group>
    <arm_group_label>Intra-Articular Hyaluronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hylan G-F 20 (high molecular weight hyaluronic acid):
intra-articular administration
6 mL
administered every 6 months
for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution:
intra-articular administration
6 mL
administered every 6 months
for 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intra-Articular Hyaluronic Acid</intervention_name>
    <arm_group_label>Intra-Articular Hyaluronic Acid</arm_group_label>
    <other_name>hylan GF-20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic knee OA as defined by the ACR clinical and radiographic criteria

          -  Kellgren-Lawrence grade of II or III on prior x-rays (taken within 6 months of the
             screen visit) or screen X-ray

          -  A minimum medial and/or lateral JSW of the target knee of 2 mm

          -  Knee pain of 40 mm or greater on a 100 mm visual analogue scale (VAS) at any time
             during the week before inclusion

          -  Oral corticosteroids (≤10 mg/day prednisolone or equivalent), NSAIDs, and
             acetaminophen are permitted if the dose had been stable for at least one month prior
             to baseline

        Exclusion Criteria:

          -  Body mass index greater than 40 kg/m2

          -  Varus or valgus deformity of the knee &gt; 15 degrees (assessed by goniometry)

          -  History of trauma, surgery or planned surgery to the study joint (including
             arthroscopy surgery), joint inflammatory diseases, septic arthritis and/or
             microcrystalline arthropathies

          -  Coagulation/platelet disorders

          -  Active malignancy, active systemic infection, or any contraindication to MRI

          -  Potent analgesics including opiates, oral corticosteroid therapy within one month
             prior to enrolment into the study other than stable doses of ≤ 10 mg daily
             prednisolone or equivalent

          -  Knee administration of intra-articular steroids in the previous 3 months or HA
             injections during the past year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime C Branco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEDOC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Sepriano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro Hospitalar de Lisboa Ocidental</affiliation>
  </overall_official>
  <overall_official>
    <last_name>João Gomes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Hospitalar de Lisboa Ocidental</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Sepriano, MD</last_name>
    <email>alexsepriano@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Ocidental - Hospital Egas Moniz</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Branco, MD, PhD</last_name>
      <phone>00351 - 21 043 10 00</phone>
    </contact>
    <investigator>
      <last_name>Jaime C Branco, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Pimentel-Santos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandre Sepriano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>João L Gomes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Pedrosa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sofia Serra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Falcão, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Canhão, MD, PhD</last_name>
      <phone>00351 - 21 780 5000</phone>
    </contact>
    <investigator>
      <last_name>Helena Canhão, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria João Gonçalves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasco Romão, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikita Khmelinskii, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sílvia Silva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquim Polido-Pereira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Morais Castro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando Saraiva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>October 31, 2014</last_update_submitted>
  <last_update_submitted_qc>October 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Intra-Articular Hyaluronic Acid</keyword>
  <keyword>disease modifying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

